What is Optune Lua?
Patients remain at the heart of the work we do every day, including our innovations in the Optune Lua device for patients living with MPM
Second-generation Optune Lua system
Designed for patient convenience, carrying comfort and usability—the second-generation Optune Lua system is1:
Compact
- Small profile carrying case with easy-grip texture
Convenient
- 5 different ways to carry the device
Equipped with smart technology
- Battery indicator alerts patients to change battery and light sensor auto-dims for night use
Loco-regional delivery of Tumor Treating Fields (TTFields) via transducer arrays provides antimitotic activity directly at the site of the malignancy2
Actor portrayal
- TTFields are added to pemetrexed + cisplatin or carboplatin systemic therapies
- The size and placement of transducer arrays are customized based on gender, body type, and tumor location
- Novocure® will provide a customized map for array placement based on patient-specific measurements and tumor location (determined via CT scans).
- It is recommended that Optune Lua is turned on at least 75% of the time (18 hours per day)
- Patients have the flexibility to decide which times of the day are best for them, including at night when sleeping
MPM, malignant pleural mesothelioma.
References: 1. Optune Lua. Patient Information and Operation Manual for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. 2. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021.